After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide).

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.

Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— when used to treat overweight or obesity.